Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2025)
Sagimet Biosciences' (SGMT) quarterly Long-Term Investments came in at $8.8 million in Q3 2025, down 49.6% year-on-year from $17.5 million in Q3 2024, and down 12.46% quarter-over-quarter from $10.1 million in Q2 2025.
Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2025) Analysis & Trends
Sagimet Biosciences' Long-Term Investments history runs 2 years deep, the most recent figure standing at $8.8 million for Q3 2025.
- On a quarterly basis, Long-Term Investments fell 49.6% year-over-year to $8.8 million in Q3 2025; TTM through Sep 2025 was $8.8 million, a 49.6% decrease from a year earlier, with the FY2024 full-year figure at $7.4 million, changed N/A from the prior year.
- Long-Term Investments declined to $8.8 million in Q3 2025 per SGMT's latest filing, from $10.1 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $22.1 million in Q2 2024 and bottomed at $7.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Sagimet Biosciences | 228.24 Mn | 228.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8.81 Mn |
| Jun 30, 2025 | 10.06 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 17.47 Mn |
| Jun 30, 2024 | 22.12 Mn |